

# Algernon Pharmaceuticals Inc.

21:15 27 Jul 2020

## Proactive virtual event to showcase four companies on the fast track to growth

Proactive, a digital financial news organization, will be showcasing four intrepid companies on the fast track to growth at its latest North American virtual investor conference.

The event will feature live webcast presentations and delegates will be given the opportunity to put their questions to the corporate presenters at a Q&A to be moderated by Proactive's Christine Corrado.

Joining Proactive's One2One Virtual Investor Forum at 1 pm ET on July 28 are:

- Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF)
- Clean Seed Capital Group (CVE:CSX) (OTCMKTS:CLGPF)
- MamaMancini's Holdings Inc (OTCMKTS:MMMB)
- Alpine 4 Technologies Limited (OTCQB: ALPP)

### Betting big on Ifenprodil

Algernon Pharmaceuticals has been nimble — and unusual — in its hunt for a coronavirus (COVID-19) drug. The company has taken a generic neurological drug that Sanofi developed in the 1970's called Ifenprodil, which is approved for use in South Korea and Japan, and is attempting to repurpose it as a potential treatment.

The Vancouver-based clinical-stage pharmaceutical company is launching a multinational Phase 2b/3 human trial of its lead drug NP-120 (Ifenprodil) as a potential treatment for COVID-19 sufferers. Enrollment of the first patient for the multinational study is expected before the end of July 2020.

"It's interesting that our lead drug NP-120 is a neurological drug that we are trying to repurpose for lung diseases," Algernon Pharmaceuticals CEO Christopher J Moreau told Proactive.

**READ:** Algernon unveils first US clinical trial site in Florida for Phase 2b/3 human study of Ifenprodil

"Interestingly, when we began this journey, we didn't know which of the 11 drugs we started investigating for new diseases would end up where we are today. Here we are with Ifenprodil as the lead," added Moreau, who will talk about the company's promising pipeline at the virtual investor event.


Algernon is also steadily advancing NP-120 (Ifenprodil) as a possible treatment for idiopathic pulmonary fibrosis, acute lung injury, and chronic cough. Additionally, the company is focused on the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Algernon's key compounds were identified using a drug repurposing strategy.

### Clean Seed's SMART farming technologies

**Price:** 0.305

**Market Cap:** \$33.57 m

#### 1 Year Share Price Graph



December 2019 June 2020 November 20

#### Share Information

**Code:** AGN

**Listing:** CSE

**52 week High Low**  
0.58 0.045

**Sector:** Pharma & Biotech

**Website:** algernonpharmaceuticals.com

#### Company Synopsis:

*Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Algernon's key compounds were identified using a drug repurposing strategy.*

action@proactiveinvestors.com

Clean Seed Capital Group is working full tilt at driving technology advancements in farming. The Canadian company has created the CX-6 SMART Seeder, a machine with the ability to plant six different crops, at three different depths with military precision.

The beauty of the CX-6 SMART Seeder for farmers and agriculture scientists is that the hulking high-output planter is wirelessly controlled through a tablet running on the company's intuitive SeedSync software system.

**WATCH:** Clean Seed to deploy their patented SMART technologies to modernize the agricultural sector

Clean Seed has not stopped with the CX-6 SMART seeder, but has just rolled out a highly advanced, lighter version of its planter. The company teamed up with joint venture partner North Dakota-based Norwood to give farmers the new Smart Seeder Max and Smart Seeder Max S.

"This partnership optimizes our ability to deliver growth, rapidly and reliably with an invested partner. Our teams are also collaborating on several additional opportunities that will further differentiate our offerings," according to Clean Seed CEO Graeme Lempriere.

### **Serving up profits**

MamaMancini's Holdings, a specialty Italian food company known for its signature beef, turkey, chicken, and pork meatballs with slow-cooked Italian sauces, is expanding into plant-based products by teaming up with Beyond Meat Inc (NASDAQ:BYND).

East Rutherford, New Jersey-based MamaMancini's said it has seen strong sales as Americans stocked up on packaged food products during the coronavirus lockdown. The company offers 20 products sold through 45,000 stores, including Whole Foods and Costco (NASDAQ:COST).

"Consumers are looking for delicious, plant-based proteins and our meatballs are the perfect solution as Beyond Beef's high quality, texture, taste and nutritional profile meet all major consumer expectations," MamaMancini's CEO Carl Wolf told Proactive.

**WATCH:** MamaMancini's expecting major rollouts on plant-based products

"As the country returns to normal activities, we believe the trend toward plant-based options will continue to grow," he added.

For its fiscal first quarter ended April 30, 2020, MamaMancini's posted \$11.1 million in revenue, a 51% jump, compared to \$7.4 million in the same period a year earlier. Gross profit increased to \$3.7 million, or 34% of total revenues, in the first quarter of 2021, compared to \$2.4 million.

### **Embodiment of Americana**

Alpine 4 Technologies Ltd (OTCQB:ALPP) is a technology holding company that provides electronic contract manufacturing solutions in the US. It has business ventures in automotive technologies, electronics manufacturing, fabrication technologies and clean energy solutions.

The Phoenix-based group acquires businesses that fit into its disruptive "DSF business model" of "drivers, stabilizers, and facilitators." Alpine 4 believes its holdings should be synergistic and collaborate across various industries spawning new ideas and competitive advantages.

Alpine 4 Technologies CEO Kent Wilson said: "We are delighted to present at the Proactive Investors One2One event. Alpine 4 will be conducting a series of interviews, and roadshow events in July, August and September and this event will kick off our Q3 corporate awareness campaign."

"Alpine 4 is the embodiment of 'Americana.' Our products and services are made in the USA and we are proud of it," he

added.

The company has issued preliminary second-quarter revenue guidance of around \$8.8 million, which is a 36% jump compared to revenue of \$5.64 million posted in the same period in 2019.

Proactive is one of the fastest-growing financial media portals in the world, providing breaking news and analysis on companies across the globe. Proactive regularly organizes large investor events in London, New York, and Sydney.

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).